Tavares FX - Search Results

1

Ketoheterocycle-based inhibitors of cathepsin K: a novel entry into the synthesis of peptidic ketoheterocycles.

Tavares FX, Deaton DN, Miller AB, Miller LR, Wright LL. Tavares FX, et al. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3891-5. doi: 10.1016/j.bmcl.2005.05.091. Bioorg Med Chem Lett. 2005. PMID: 15993587

2

Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.

Tavares FX, Boncek V, Deaton DN, Hassell AM, Long ST, Miller AB, Payne AA, Miller LR, Shewchuk LM, Wells-Knecht K, Willard DH Jr, Wright LL, Zhou HQ. Tavares FX, et al. J Med Chem. 2004 Jan 29;47(3):588-99. doi: 10.1021/jm030373l. J Med Chem. 2004. PMID: 14736240

3

Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.

Barrett DG, Catalano JG, Deaton DN, Long ST, Miller LR, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ. Barrett DG, et al. Among authors: tavares fx. Bioorg Med Chem Lett. 2004 May 17;14(10):2543-6. doi: 10.1016/j.bmcl.2004.02.085. Bioorg Med Chem Lett. 2004. PMID: 15109647

4

Potent and selective ketoamide-based inhibitors of cysteine protease, cathepsin K.

Tavares FX, Deaton DN, Miller AB, Miller LR, Wright LL, Zhou HQ. Tavares FX, et al. J Med Chem. 2004 Oct 7;47(21):5049-56. doi: 10.1021/jm0400799. J Med Chem. 2004. PMID: 15456248

5

Ketoamide-based inhibitors of cysteine protease, cathepsin K: P3 modifications.

Tavares FX, Deaton DN, Miller LR, Wright LL. Tavares FX, et al. J Med Chem. 2004 Oct 7;47(21):5057-68. doi: 10.1021/jm040107n. J Med Chem. 2004. PMID: 15456249

6

Novel and potent cyclic cyanamide-based cathepsin K inhibitors.

Deaton DN, Hassell AM, McFadyen RB, Miller AB, Miller LR, Shewchuk LM, Tavares FX, Willard DH Jr, Wright LL. Deaton DN, et al. Among authors: tavares fx. Bioorg Med Chem Lett. 2005 Apr 1;15(7):1815-9. doi: 10.1016/j.bmcl.2005.02.033. Bioorg Med Chem Lett. 2005. PMID: 15780613

7

P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.

Barrett DG, Boncek VM, Catalano JG, Deaton DN, Hassell AM, Jurgensen CH, Long ST, McFadyen RB, Miller AB, Miller LR, Payne JA, Ray JA, Samano V, Shewchuk LM, Tavares FX, Wells-Knecht KJ, Willard DH Jr, Wright LL, Zhou HQ. Barrett DG, et al. Among authors: tavares fx. Bioorg Med Chem Lett. 2005 Aug 1;15(15):3540-6. doi: 10.1016/j.bmcl.2005.05.062. Bioorg Med Chem Lett. 2005. PMID: 15982880

8

Design of cathepsin K inhibitors for osteoporosis.

Deaton DN, Tavares FX. Deaton DN, et al. Among authors: tavares fx. Curr Top Med Chem. 2005;5(16):1639-75. doi: 10.2174/156802605775009676. Curr Top Med Chem. 2005. PMID: 16375747 Review.

9

Acyclic, orally bioavailable ketone-based cathepsin K inhibitors.

Barrett DG, Catalano JG, Deaton DN, Long ST, McFadyen RB, Miller AB, Miller LR, Samano V, Tavares FX, Wells-Knecht KJ, Wright LL, Zhou HQ. Barrett DG, et al. Among authors: tavares fx. Bioorg Med Chem Lett. 2007 Jan 1;17(1):22-7. doi: 10.1016/j.bmcl.2006.10.102. Epub 2006 Nov 17. Bioorg Med Chem Lett. 2007. PMID: 17157021

10

N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.

Tavares FX, Boucheron JA, Dickerson SH, Griffin RJ, Preugschat F, Thomson SA, Wang TY, Zhou HQ. Tavares FX, et al. J Med Chem. 2004 Sep 9;47(19):4716-30. doi: 10.1021/jm040063i. J Med Chem. 2004. PMID: 15341487

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page